Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in Oncol Rep

Retrieve available abstracts of 108 articles:
HTML format



Single Articles


    September 2022
  1. ZHANG G, Zheng H, Wang L
    miR4913p functions as a tumor suppressor in nonsmall cell lung cancer by targeting fibroblast growth factor 5.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


  2. ZHU H, Xu X, Zheng E, Ni J, et al
    LncRNA RP11805J14.5 functions as a ceRNA to regulate CCND2 by sponging miR34b3p and miR1395p in lung adenocarcinoma.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


    August 2022
  3. AN W, Zhang Y, Lai H, Zhang Y, et al
    Alpinia katsumadai Hayata induces growth inhibition and autophagyrelated apoptosis by regulating the AMPK and Akt/mTOR/p70S6K signaling pathways in cancer cells.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


  4. ZHANG J, Wang J, Wu J, Huang J, et al
    UBE2T regulates FANCI monoubiquitination to promote NSCLC progression by activating EMT.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


    July 2022
  5. LI H, Zhong R, He C, Tang C, et al
    Colonystimulating factor CSF2 mediates the phenotypic plasticity of smallcell lung cancer by regulating the pSTAT3/MYC pathway.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


  6. ZHOU F, Nie L, Feng D, Guo S, et al
    [Retracted] MicroRNA379 acts as a tumor suppressor in nonsmall cell lung cancer by targeting the IGF1Rmediated AKT and ERK pathways.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


  7. HUANG X, Jiang L, Lu S, Yuan M, et al
    Overexpression of ERCC6L correlates with poor prognosis and confers malignant phenotypes of lung adenocarcinoma.
    Oncol Rep. 2022;48.
    PubMed     Abstract available


    June 2022
  8. YAMAZAKI K, Hoshi M, Tezuka H, Morita N, et al
    Dallose enhances the efficacy of hydroxychloroquine against Lewis lung carcinoma cell growth by inducing autophagy.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


  9. ZHU F, Ren Z
    Icariin inhibits the malignant progression of lung cancer by affecting the PI3K/Akt pathway through the miR2055p/PTEN axis.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


    April 2022
  10. SUZUKI T, Sirimangkalakitti N, Baba A, Toyoshima-Nagasaki R, et al
    Characterization of the nucleotide excision repair pathway and evaluation of compounds for overcoming the cisplatin resistance of nonsmall cell lung cancer cell lines.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


  11. SUMITOMO R, Huang CL, Fujita M, Cho H, et al
    Differential expression of PDL1 and PDL2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in nonsmall cell lung cancer.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


  12. CAO J, Yu U, Li L, Yuan X, et al
    circKL inhibits the growth and metastasis of kidney cancer by sponging miR1825p and upregulating FBXW7.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


    March 2022
  13. CHEN N, Zhou YS, Wang LC, Huang JB, et al
    Advances in metforminbased metabolic therapy for nonsmall cell lung cancer (Review).
    Oncol Rep. 2022;47.
    PubMed     Abstract available


  14. SHI Q, Shi QN, Xu JW, Wang HY, et al
    rs9390123 and rs9399451 influence the DNA repair capacity of lung cancer by regulating PEX3 and PHACTR2AS1 expression instead of PHACTR2.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


  15. WANG Y, Chen J, Huang Y, Yang S, et al
    Schisandrin B suppresses osteosarcoma lung metastasis in vivo by inhibiting the activation of the Wnt/betacatenin and PI3K/Akt signaling pathways.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


    February 2022
  16. LI Z, Li B, Niu L, Ge L, et al
    [Retracted] miR592 functions as a tumor suppressor in human nonsmall cell lung cancer by targeting SOX9.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


  17. HORIBE S, Ishikawa K, Nakada K, Wake M, et al
    Mitochondrial DNA mutations are involved in the acquisition of cisplatin resistance in human lung cancer A549 cells.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


  18. FUJII Y, Amatya VJ, Kushitani K, Suzuki R, et al
    Downregulation of lncRNA PVT1 inhibits proliferation and migration of mesothelioma cells by targeting FOXM1.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


    January 2022
  19. KEERATICHAMROEN S, Lirdprapamongkol K, Thongnest S, Boonsombat J, et al
    JAK2/STAT3mediated dosedependent cytostatic and cytotoxic effects of sesquiterpene lactones from Gymnanthemum extensum on A549 human lung carcinoma cells.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


  20. SONODA D, Kamizaki K, Matsuo Y, Aruga K, et al
    Characterization of morphological alterations in micropapillary adenocarcinoma of the lung using an established cell line.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


  21. FAN M, Arai M, Tawada A, Chiba T, et al
    Contrasting functions of the epithelialstromal interaction 1 gene, in human oral and lung squamous cell cancers.
    Oncol Rep. 2022;47.
    PubMed     Abstract available


    November 2021
  22. ZENG Y, Lv X, Du J
    Natural killer cellbased immunotherapy for lung cancer: Challenges and perspectives (Review).
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    October 2021
  23. HUA X, Chu H, Wang C, Shi X, et al
    Targeting USP22 with miR305p to inhibit the hypoxiainduced expression of PDL1 in lung adenocarcinoma cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    September 2021
  24. CHANG CY, Wu KL, Chang YY, Tsai PH, et al
    Amine oxidase, copper containing 3 exerts antimesenchymal transformation and enhances CD4(+) Tcell recruitment to prolong survival in lung cancer.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  25. ZHANG Y, Yao H, Li Y, Yang L, et al
    Circular RNA TADA2A promotes proliferation and migration via modulating of miR638/KIAA0101 signal in nonsmall cell lung cancer.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  26. JIN C, Shi L, Li K, Liu W, et al
    Mechanism of tumorderived extracellular vesicles in regulating renal cell carcinoma progression by the delivery of MALAT1.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  27. WANG WJ, Wang J, Ouyang C, Chen C, et al
    Overview of serpin B9 and its roles in cancer (Review).
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    August 2021
  28. KIM MK, Choi MJ, Lee HM, Choi HS, et al
    Heterogeneous nuclear ribonucleoprotein A2/B1 regulates the ERK and p53/HDM2 signaling pathways to promote the survival, proliferation and migration of nonsmall cell lung cancer cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  29. LIN CC, Liao WT, Yang TY, Lu HJ, et al
    MicroRNA10b modulates cisplatin tolerance by targeting p53 directly in lung cancer cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  30. ZHANG X, He Y, Jiang Y, Bao Y, et al
    TMEM229A suppresses nonsmall cell lung cancer progression via inactivating the ERK pathway.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  31. LU R, Zhou Q, Ju L, Chen L, et al
    Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  32. MA J, Yan T, Bai Y, Ye M, et al
    TMEM100 negatively regulated by microRNA106b facilitates cellular apoptosis by suppressing survivin expression in NSCLC.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  33. YANG L, Li N, Wang M, Zhang YH, et al
    Tumorigenic effect of TERT and its potential therapeutic target in NSCLC (Review).
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  34. ZHANG Y, Liu S, Zhao T, Dang C, et al
    METTL3mediated m6A modification of Bcl2 mRNA promotes nonsmall cell lung cancer progression.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  35. ZHU Y, Chen QY, Jordan A, Sun H, et al
    RUNX2/miR31/SATB2 pathway in nickelinduced BEAS2B cell transformation.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    July 2021
  36. ZINNAH KMA, Park SY
    Sensitizing TRAILresistant A549 lung cancer cells and enhancing TRAILinduced apoptosis with the antidepressant amitriptyline.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  37. ZENG T, Xu M, Zhang W, Gu X, et al
    Autophagy inhibition and microRNA199a5p upregulation in paclitaxelresistant A549/T lung cancer cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    June 2021
  38. BUACHAN P, Namsa-Aid M, Sung HK, Peng C, et al
    Inhibitory effects of terrein on lung cancer cell metastasis and angiogenesis.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  39. GAO L, Yang T, Zhang S, Liang Y, et al
    EHF enhances malignancy by modulating AKT and MAPK/ERK signaling in nonsmall cell lung cancer cells.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  40. LI S, Wang H, Ma R, Wang L, et al
    Schisandrin B inhibits epithelialmesenchymal transition and stemness of largecell lung cancer cells and tumorigenesis in xenografts via inhibiting the NFkappaB and p38 MAPK signaling pathways.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  41. WANG Z, Zhang X, Tian X, Yang Y, et al
    CREB stimulates GPX4 transcription to inhibit ferroptosis in lung adenocarcinoma.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  42. GLATZEL-PLUCINSKA N, Piotrowska A, Rzechonek A, Podhorska-Okolow M, et al
    SATB1 protein is associated with the epithelialmesenchymal transition process in nonsmall cell lung cancers.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


    May 2021
  43. GAO Y, Zhang G, Liu J, Li H, et al
    Tissue-specific transplantation antigen P35B functions as an oncogene and is regulated by microRNA-125a-5p in lung cancer.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  44. WANG WJ, Ouyang C, Yu B, Chen C, et al
    Role of hypoxiainducible factor2alpha in lung cancer (Review).
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  45. LIAO H, Liang Y, Kang L, Xiao Y, et al
    miR4543p inhibits nonsmall cell lung cancer cell proliferation and metastasis by targeting TGFB2.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  46. HE Q, Dong Y, Zhu Y, Ding Z, et al
    TMEM100 induces cell death in nonsmall cell lung cancer via the activation of autophagy and apoptosis.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  47. WANG H, Zhang P
    lncRNACASC15 promotes osteosarcoma proliferation and metastasis by regulating epithelialmesenchymal transition via the Wnt/betacatenin signaling pathway.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  48. ZHOU X, Sun T, Meng Y, Luo J, et al
    BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  49. ZHOU H, Geng F, Chen Y, Du J, et al
    The mineral dust-induced gene, mdig, regulates angiogenesis and lymphangiogenesis in lung adenocarcinoma by modulating the expression of VEGF-A/C/D via EGFR and HIF-1alpha signaling.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  50. LIN S, Tian C, Li J, Liu B, et al
    Differential MUC22 expression by epigenetic alterations in human lung squamous cell carcinoma and adenocarcinoma.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


    April 2021
  51. LI S, Liu Y, Qiu G, Luo Y, et al
    Emerging roles of circular RNAs in nonsmall cell lung cancer (Review).
    Oncol Rep. 2021;45:1.
    PubMed     Abstract available


  52. HU Y, Cui J, Jin L, Su Y, et al
    LRPPRC contributes to the cisplatin resistance of lung cancer cells by regulating MDR1 expression.
    Oncol Rep. 2021;45:1.
    PubMed     Abstract available


  53. MURPHY A, Roy N, Sun H, Jin C, et al
    Induction of NUPR1 and AP1 contributes to the carcinogenic potential of nickel.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  54. HOSSIAN AKMN, Mackenzie GG, Mattheolabakis G
    Combination of miR143 and miR506 reduces lung and pancreatic cancer cell growth through the downregulation of cyclindependent kinases.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


    March 2021
  55. YANG XG, Li YY, Zhao DX, Cui W, et al
    Repurposing of a monoamine oxidase A inhibitorheptamethine carbocyanine dye conjugate for paclitaxelresistant nonsmall cell lung cancer.
    Oncol Rep. 2021;45:1306-1314.
    PubMed     Abstract available


  56. LING B, Wei P, Xiao J, Cen B, et al
    Nucleolar and spindleassociated protein 1 promotes nonsmall cell lung cancer progression and serves as an effector of myocyte enhancer factor 2D.
    Oncol Rep. 2021;45:1044-1058.
    PubMed     Abstract available


  57. GU X, Zhang J, Shi Y, Shen H, et al
    ESM1/HIF1alpha pathway modulates chronic intermittent hypoxiainduced nonsmallcell lung cancer proliferation, stemness and epithelialmesenchymal transition.
    Oncol Rep. 2021;45:1226-1234.
    PubMed     Abstract available


    January 2021
  58. ZAAROUR RF, Prasad P, Venkatesh GH, Khouzam RA, et al
    Waterpipe smoke condensate influences epithelial to mesenchymal transition and interferes with the cytotoxic immune response in non-small cell lung cancer cell lines.
    Oncol Rep. 2021 Jan 18. doi: 10.3892/or.2021.7938.
    PubMed     Abstract available


  59. LI M, Chen R, Ji B, Fan C, et al
    Role of ERCC5 polymorphisms in nonsmall cell lung cancer risk and responsiveness/toxicity to cisplatinbased chemotherapy in the Chinese population.
    Oncol Rep. 2021 Jan 14. doi: 10.3892/or.2021.7935.
    PubMed     Abstract available


  60. XIAO L, Mao Y, Tong Z, Zhao Y, et al
    Radiation exposure triggers the malignancy of nonsmall cell lung cancer cells through the activation of visfatin/Snail signaling.
    Oncol Rep. 2021 Jan 8. doi: 10.3892/or.2021.7929.
    PubMed     Abstract available


  61. ZHOU X, Liu B, Ning Q, Xia Z, et al
    Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFRmutated NSCLC cells in vitro and in vivo via STAT3/Bcl2 signaling.
    Oncol Rep. 2021;45:217-229.
    PubMed     Abstract available


    December 2020
  62. ZHU Z, Wu Q, Zhang M, Tong J, et al
    Hsa_circ_0016760 exacerbates the malignant development of nonsmall cell lung cancer by sponging miR1455p/FGF5.
    Oncol Rep. 2020 Dec 14. doi: 10.3892/or.2020.7899.
    PubMed     Abstract available


  63. YANG X, Gao Y, Liu Q, Wan L, et al
    Zoledronic acid resensitises gefitinibresistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelialmesenchymal transition.
    Oncol Rep. 2020 Dec 3. doi: 10.3892/or.2020.7881.
    PubMed     Abstract available


    November 2020
  64. ZHAO D, Chen J, Long X, Wang J, et al
    Dose adjustment for tyrosine kinase inhibitors in nonsmall cell lung cancer patients with hepatic or renal function impairment (Review).
    Oncol Rep. 2020 Nov 27. doi: 10.3892/or.2020.7870.
    PubMed     Abstract available


  65. YANG H, Zhan L, Yang T, Wang L, et al
    [Corrigendum] Ski prevents TGFbetainduced EMT and cell invasion by repressing SMADdependent signaling in nonsmall cell lung cancer.
    Oncol Rep. 2020 Nov 25. doi: 10.3892/or.2020.7868.
    PubMed     Abstract available


  66. OUYANG L, Yang M, Wang X, Fan J, et al
    Long noncoding RNA FER1L4 inhibits cell proliferation and promotes cell apoptosis via the PTEN/AKT/p53 signaling pathway in lung cancer.
    Oncol Rep. 2020 Nov 19. doi: 10.3892/or.2020.7861.
    PubMed     Abstract available


  67. WANG L, Wang W
    Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in nonsmall cell lung cancer (Review).
    Oncol Rep. 2020 Nov 13. doi: 10.3892/or.2020.7851.
    PubMed     Abstract available


  68. HASE H, Aoki M, Matsumoto K, Nakai S, et al
    Cancer typeSLCO1B3 promotes epithelialmesenchymal transition resulting in the tumour progression of nonsmall cell lung cancer.
    Oncol Rep. 2020 Nov 6. doi: 10.3892/or.2020.7839.
    PubMed     Abstract available


  69. JIN D, Wu Y, Shao C, Gao Y, et al
    [Retracted] Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human nonsmall lung cancer cells by regulating the YAP pathway.
    Oncol Rep. 2020 Nov 2. doi: 10.3892/or.2020.7830.
    PubMed     Abstract available


  70. REN T, Tang YJ, Wang MF, Wang HS, et al
    Triptolide induces apoptosis through the calcium/calmodulindependent protein kinase kinasebeta/AMPactivated protein kinase signaling pathway in nonsmall cell lung cancer cells.
    Oncol Rep. 2020;44:2288-2296.
    PubMed     Abstract available


    October 2020
  71. CUI XY, Park SH, Park WH
    Auranofin inhibits the proliferation of lung cancer cells via necrosis and caspasedependent apoptosis.
    Oncol Rep. 2020 Oct 21. doi: 10.3892/or.2020.7818.
    PubMed     Abstract available


  72. PARK WH
    Propyl gallate reduces the growth of lung cancer cells through caspasedependent apoptosis and G1 phase arrest of the cell cycle.
    Oncol Rep. 2020 Oct 20. doi: 10.3892/or.2020.7815.
    PubMed     Abstract available


  73. XU L, Qu JL, Song N, Zhang LY, et al
    Biological and clinical significance of flap endonuclease1 in triplenegative breast cancer: Support of metastasis and a poor prognosis.
    Oncol Rep. 2020 Oct 16. doi: 10.3892/or.2020.7812.
    PubMed     Abstract available


    September 2020
  74. ZHAO X, Li M, Dai X, Yang Y, et al
    Downregulation of exosomal miR1273a increases cisplatin resistance of nonsmall cell lung cancer by upregulating the expression of syndecan binding protein.
    Oncol Rep. 2020 Sep 4. doi: 10.3892/or.2020.7753.
    PubMed     Abstract available


  75. WANG X, Zhang G, Cheng Z, Dai L, et al
    Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR98 in lung cancer cells.
    Oncol Rep. 2020;44:1025-1036.
    PubMed     Abstract available


  76. ZHAO Y, Ye X, Chen R, Gao Q, et al
    Sirtuin 7 promotes nonsmall cell lung cancer progression by facilitating G1/S phase and epithelialmesenchymal transition and activating AKT and ERK1/2 signaling.
    Oncol Rep. 2020;44:959-972.
    PubMed     Abstract available


  77. SUN L, Yuan W, Wen G, Yu B, et al
    Parthenolide inhibits human lung cancer cell growth by modulating the IGF1R/PI3K/Akt signaling pathway.
    Oncol Rep. 2020;44:1184-1193.
    PubMed     Abstract available


  78. LI W, Li C, Ma L, Jin F, et al
    Resveratrol inhibits viability and induces apoptosis in the smallcell lung cancer H446 cell line via the PI3K/Akt/cMyc pathway.
    Oncol Rep. 2020 Sep 1. doi: 10.3892/or.2020.7747.
    PubMed     Abstract available


    August 2020
  79. LI D, Wang L, Feng J, Shen YW, et al
    RP11284F21.9 promotes lung carcinoma proliferation and invasion via the regulation of miR6273p/CCAR1.
    Oncol Rep. 2020 Aug 12. doi: 10.3892/or.2020.7732.
    PubMed     Abstract available


  80. GUAN Y, Yang J, Liu X, Chu L, et al
    Long noncoding RNA CBR3 antisense RNA 1 promotes the aggressive phenotypes of nonsmallcell lung cancer by sponging microRNA5093p and competitively upregulating HDAC9 expression.
    Oncol Rep. 2020 Aug 7. doi: 10.3892/or.2020.7719.
    PubMed     Abstract available


  81. LIU X, Huang S, Guan Y, Zhang Q, et al
    Long noncoding RNA OSER1AS1 promotes the malignant properties of nonsmall cell lung cancer by sponging microRNA4333p and thereby increasing Smad2 expression.
    Oncol Rep. 2020;44:599-610.
    PubMed     Abstract available


    July 2020
  82. GAO F, Li M, Zhou L, Liu W, et al
    Xanthohumol targets the ERK1/2Fra1 signaling axis to reduce cyclin D1 expression and inhibit nonsmall cell lung cancer.
    Oncol Rep. 2020 Jul 20. doi: 10.3892/or.2020.7697.
    PubMed     Abstract available


  83. WANG L, Wu L, Pang J
    Long noncoding RNA PSMA3AS1 functions as a microRNA4093p sponge to promote the progression of nonsmall cell lung carcinoma by targeting spindlin 1.
    Oncol Rep. 2020 Jul 15. doi: 10.3892/or.2020.7693.
    PubMed     Abstract available


    June 2020
  84. CHEN J, Lin Q, Ni T, Zhao J, et al
    NLK interacts with 1433zeta to restore the expression of Ecadherin.
    Oncol Rep. 2020;43:1845-1852.
    PubMed     Abstract available


  85. HUANG T, Ren K, Ding G, Yang L, et al
    miR10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
    Oncol Rep. 2020;43:1906-1914.
    PubMed     Abstract available


    May 2020
  86. WU X, Li X, Xu G
    Propofol suppresses the progression of nonsmall cell lung cancer via downregulation of the miR215p/MAPK10 axis.
    Oncol Rep. 2020 May 21. doi: 10.3892/or.2020.7619.
    PubMed     Abstract available


  87. DONG S, Men W, Yang S, Xu S, et al
    Identification of lung adenocarcinoma biomarkers based on bioinformatic analysis and human samples.
    Oncol Rep. 2020;43:1437-1450.
    PubMed     Abstract available


    April 2020
  88. EGUCHI R, Wakabayashi I
    HDGF enhances VEGFdependent angiogenesis and FGF2 is a VEGFindependent angiogenic factor in nonsmall cell lung cancer.
    Oncol Rep. 2020 Apr 9. doi: 10.3892/or.2020.7580.
    PubMed     Abstract available


  89. DU W, Sun L, Liu T, Zhu J, et al
    The miR6253p/AXL axis induces nonT790M acquired resistance to EGFRTKI via activation of the TGFbeta/Smad pathway and EMT in EGFRmutant nonsmall cell lung cancer.
    Oncol Rep. 2020 Apr 8. doi: 10.3892/or.2020.7579.
    PubMed     Abstract available


  90. FAN S, Liao Y, Qiu W, Huang Q, et al
    Estrogen promotes the metastasis of nonsmall cell lung cancer via estrogen receptor beta by upregulation of Tolllike receptor 4 and activation of the myd88/NFkappaB/MMP2 pathway.
    Oncol Rep. 2020 Apr 2. doi: 10.3892/or.2020.7574.
    PubMed     Abstract available


  91. YANG MQ, Bai LL, Lei L, Zheng YW, et al
    DEK promotes the proliferation and invasion of lung cancers and indicates poor prognosis in lung adenocarcinomas.
    Oncol Rep. 2020;43:1338-1348.
    PubMed     Abstract available


  92. BAI L, Liang J, Li L, Li E, et al
    Downregulation of MiD49 contributes to tumor growth and metastasis of human pancreatic cancer.
    Oncol Rep. 2020;43:1208-1220.
    PubMed     Abstract available


    March 2020
  93. LV L, Zhang W, Li T, Jiang L, et al
    Hispidulin exhibits potent anticancer activity in vitro and in vivo through activating ER stress in nonsmallcell lung cancer cells.
    Oncol Rep. 2020 Mar 30. doi: 10.3892/or.2020.7568.
    PubMed     Abstract available


  94. WANG J, Zhang ZQ, Li FQ, Chen JN, et al
    Triptolide interrupts rRNA synthesis and induces the RPL23MDM2p53 pathway to repress lung cancer cells.
    Oncol Rep. 2020 Mar 30. doi: 10.3892/or.2020.7569.
    PubMed     Abstract available


  95. WEI M, Li J, Qiu J, Yan Y, et al
    Costunolide induces apoptosis and inhibits migration and invasion in H1299 lung cancer cells.
    Oncol Rep. 2020 Mar 26. doi: 10.3892/or.2020.7566.
    PubMed     Abstract available


  96. HU J, Shang Y, Shi X, Zhang S, et al
    Characterization of genomic alterations and the significance of PI3K/mTOR pathway mutations and tumor mutational burden in nonsmall cell lung cancer.
    Oncol Rep. 2020 Mar 23. doi: 10.3892/or.2020.7559.
    PubMed     Abstract available


  97. LI F, Cui H, Jin X, Gong X, et al
    Triptolide inhibits epithelialmesenchymal transition and induces apoptosis in gefitinibresistant lung cancer cells.
    Oncol Rep. 2020 Mar 10. doi: 10.3892/or.2020.7542.
    PubMed     Abstract available


  98. CHEN L, Ren P, Zhang Y, Gong B, et al
    Long noncoding RNA GAS5 increases the radiosensitivity of A549 cells through interaction with the miR21/PTEN/Akt axis.
    Oncol Rep. 2020;43:897-907.
    PubMed     Abstract available


    February 2020
  99. CAO F, Wang Z, Feng Y, Zhu H, et al
    lncRNA TPTEP1 competitively sponges miR3285p to inhibit the proliferation of nonsmall cell lung cancer cells.
    Oncol Rep. 2020 Feb 26. doi: 10.3892/or.2020.7522.
    PubMed     Abstract available


  100. LI J, Cui J, Li Z, Fu X, et al
    ORP8 induces apoptosis by releasing cytochrome c from mitochondria in nonsmall cell lung cancer.
    Oncol Rep. 2020 Feb 24. doi: 10.3892/or.2020.7517.
    PubMed     Abstract available


  101. ZHAO L, Wang L, Wang Y, Ma P, et al
    Long noncoding RNA CCAT1 enhances human nonsmall cell lung cancer growth through downregulation of microRNA218.
    Oncol Rep. 2020 Feb 12. doi: 10.3892/or.2020.7500.
    PubMed     Abstract available


  102. LI Y, Yin Y, Ma J, Sun Y, et al
    Combination of AAVmediated NUPR1 knockdown and trifluoperazine induces premature senescence in human lung adenocarcinoma A549 cells in nude mice.
    Oncol Rep. 2020;43:681-688.
    PubMed     Abstract available


  103. CAO PP, Chen WJ, Pang HL, Shen WW, et al
    Effect of CUL4A on the metastatic potential of lung adenocarcinoma to the bone.
    Oncol Rep. 2020;43:662-670.
    PubMed     Abstract available


  104. HU F, Li C, Zheng X, Zhang H, et al
    Lung adenocarcinoma resistance to therapy with EGFRtyrosine kinase inhibitors is related to increased expression of cancer stem cell markers SOX2, OCT4 and NANOG.
    Oncol Rep. 2020;43:727-735.
    PubMed     Abstract available


  105. WANG H, Kanmangne D, Li R, Qian Z, et al
    miR30a3p suppresses the proliferation and migration of lung adenocarcinoma cells by downregulating CNPY2.
    Oncol Rep. 2020;43:646-654.
    PubMed     Abstract available


    January 2020
  106. MIERZEJEWSKA J, Szczygiel A, Anger-Gora N, Rossowska J, et al
    DeOacylated lipooligosaccharide of E. coli B reduces the number of metastatic foci via downregulation of myeloid cell activity.
    Oncol Rep. 2020;43:270-281.
    PubMed     Abstract available


    December 2019
  107. ZHAO C, Zheng S, Yan Z, Deng Z, et al
    CCL18 promotes the invasion and metastasis of breast cancer through Annexin A2.
    Oncol Rep. 2019 Dec 11. doi: 10.3892/or.2019.7426.
    PubMed     Abstract available


    November 2019
  108. ZHANG L, Tao X, Fu Q, Ge C, et al
    Curcumin inhibits cell proliferation and migration in NSCLC through a synergistic effect on the TLR4/MyD88 and EGFR pathways.
    Oncol Rep. 2019;42:1843-1855.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: